Medicare coverage of buprenorphine-naloxone film surrounding generic entry

CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413
Source: The American Journal of Managed Care - Category: Health Management Authors: Source Type: research